Combining SBRT with Cardonilizumab and Lenvatinib for Unresectable Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the efficacy and safety of combining stereotactic body radiation therapy (SBRT) with the immune checkpoint inhibitor cardonilizumab and the targeted therapy lenvastinib in patients with unresectable hepatocellular carcinoma that has spread to the portal vein. It is a single-arm, multicenter study designed to assess how well this combination treatment works in managing the disease. Participants will be monitored for treatment response and safety outcomes throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age: 18-70 years old;
2. Eastern Cooperative Oncology Group (ECOG) -Performance Status(PS):0-2 points；
3. Hepatocellular carcinoma was diagnosed according to histopathology or the 2022 diagnostic criteria for primary liver cancer；
4. Expected survival period≥3 months;
5. Liver function grade Child-Pugh A or better grade B (7 points);
6. At least one measurable lesion:

   Liver lesion ① The Lesion can be accurately measured at least in the range of 1.0cm;

   ② The Lesion is suitable for repeated measurement;
   * The lesion shows enhanced intratumoral arteries on computed tomography (CT) or magnetic resonance imaging (MRI); Non-liver lesion In at least one dimension, the short axis of lymphadenopathy (LN) is≥1.5cm. Longest diameter of non-nodular lesions is≥1.0cm
7. The Barcelona liver cancer staging system is stage C (BCLC-C), which meets one of the following conditions:

(1) Liver tumor can be resected, which is combined with Vp 3-4 portal vein cancer thrombus; (2) Liver tumor is unresectable or has distant metastasis, and is combined with Vp1-4 type portal vein cancer thrombus; 8. The patient had not received prior systemic therapy including sorafenib, lenvatinib, chemotherapy; 9. The patient had previously received locoregional therapy (including radiofrequency or ablation therapy, percutaneous ethanol or acetic acid injection, cryotherapy, high intensity focused ultrasound, hepatic artery chemoembolization, hepatic artery embolization, etc., and the local treatment area had definite progression (according to RECIST v1.1 criteria); 10. Baseline blood routine and biochemical indicators meet the following criteria: Hemoglobin≥90g / L; Absolute neutrophil count (ANC)≥1.5× 10 \^ 9 / L; Platelet≥75×10 \^ 9 / L; ALT,AST ≤3×upper normal value (ULN); Serum total bilirubin ≤ 1.5 ×ULN; Serum creatinine ≤1.5 × ULN; Serum albumin was used for≥30g / L.

Exclusion Criteria:

1. Patients diagnosed with hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibrolaminar cell carcinoma；
2. Patients with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or planned transplantation；
3. Patients have hepatic encephalopathy (West Haven Standard Grade III, Level IV) or have moderate or severe ascites (i.e., patients requiring therapeutic puncture drainage) or have uncontrolled pleural or pericardial effusion；
4. Patients have symptomatic, untreated, or progressive central nervous system (CNS) or leptomeningeal metastases.If all the following criteria are met, asymptomatic subjects with treated CNS lesions can be enrolled.

Where it's running

• First Affiliated Hospital of Guangxi Medical University
  Nanning, Guangxi, China Recruiting

Study contacts

• Study coordinator: Ning Mo, professor
• Email: 369895025@qq.com
• Phone: 15289662269

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Neoadjuvant Cardonilizumab With Chemotherapy Before Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma

  This study tests whether adding cardonilizumab to preoperative chemotherapy (versus chemoradiotherapy) helps patients with locally advanced ESCC have a better chance at complete tumor removal and longer survival.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07699185

• Predictive biomarkers for immunotherapy in endometrial cancer

  This study tests molecular and epigenetic features to see if they can predict which endometrial cancer patients will respond to immune checkpoint inhibitors.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07690540

• Observational cohort of chronic brain viral infections (including PML)

  This project will try immune checkpoint inhibitors in people with chronic central nervous system viral infections like PML to see if they lead to better long-term outcomes.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07512518

• Conversion therapy with FOLFOX-HAIC, lenvatinib, and tislelizumab for HCC with VP3 PVTT

  This study tests a triple combination therapy to try to shrink tumors and PVTT in people with unresectable hepatocellular carcinoma to enable potential surgical removal.

  Recruiting Phase 2 First Hospital of China Medical University · Shenyang, Liaoning · NCT07483359

• Neoadjuvant therapy for early triple-negative breast cancer using QL1706 plus chemotherapy guided by response

  This study tests if adding QL1706 (a PD-1/CTLA-4 blocker) to chemotherapy before surgery can shrink early triple-negative breast tumors and spare some patients from anthracyclines.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07372079

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.